Academic manufacturing of anti-CD19 CAR-T cells from a leukapheresis with a high proportion of acute myeloid leukaemia blasts.
This report describes the manufacturing of anti-CD19 chimeric antigen receptor-T (CAR-T) cells in an academic setting for a patient with a high tumour burden (>90%) who was referred for CD19+ acute myeloid leukaemia (AML). A 30-year-old woman with refractory acute myeloid leukaemia (AML) was found with 94% circulating...